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Abstract
Parvovirus B19 infection can cause severe effects in high-risk groups including pregnant women and immunocom-
promised individuals. Although serological detection of B19 infection is commonplace, minimal information is
available on the absolute performance characteristics of various tests for the detection of B19 IgM. The performance
of the first parvovirus B19 IgM enzyme immunoassay to be cleared by the US Food and Drug Administration (FDA)
is described. The immunoassay cut-off has been established using receiver operating characteristic (ROC) analysis
giving a sensitivity and specificity of detection of 89.1 and 99.4%, respectively. No cross-reactivity is observed with
rubella or other viral disease IgM which cause similar symptomologies to parvovirus B19. Multi-site reproducibility
studies have shown high immunoassay reproducibility with detection rates (observed:expected result) of 100% for
nonreactive specimens (N324) and strongly reactive (N403), respectively. Immunoassay reproducibility ranged
from 11.76 to 17.46% coefficient of variation for all reactive specimens tested (N12) whereby each specimen was
assayed a total of 81 times. Parvovirus B19 IgM seroprevalence of 1% was observed in a US blood donor population
(N399). In the absence of international performance criteria, this study will be of major benefit to the clinical
virologist in assessing immunoassay reliability for the detection of recent infection with parvovirus B19. © 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
Since its discovery in 1975, parvovirus B19 has
been identified as the causative agent of a number
of clinical conditions in humans (Anderson et al.,
1985; Kurtzman et al., 1987). The spectrum of
symptoms caused by parvovirus B19, including
rash, arthralgia and transient aplastic crisis are
generally self-limiting in healthy individuals.
However, serious complications due to viral infec-
tion may arise in certain populations including
pregnant women, immunocompromised patients
* Corresponding author. Tel.: 353-1-7083858; fax: 353-
1-7083845.
E-mail address: sean.doyle@may.ie (S. Doyle).
0166-0934:00:$ - see front matter © 2000 Elsevier Science B.V. All rights reserved.
PII: S0166 -0934 (00 )00227 -5
S. Doyle et al. : Journal of Virological Methods 90 (2000) 143–152144
and individuals suffering from sickle cell disease
or other blood-related disorders (Serjeant et al.,
1993; Jordan, 1996; To¨ro¨k, 1997). In fact, expo-
sure to parvovirus B19 during pregnancy leads to
fetal loss occurring in 8–16% of infections (Mark
et al., 1993; Jordan, 1996).
The parvovirus B19 capsid is composed of two
structural proteins, namely VP1 (83 kDa) and
VP2 (53 kDa), with VP2 comprising approxi-
mately 95% of total capsid protein (Ozawa and
Young, 1987; Ozawa et al., 1987). Both of
these proteins have been expressed in
numerous prokaryotic and eukaryotic expression
systems in order to assess their potential use as
diagnostic reagents for parvovirus B19 infection
(Morinet et al., 1989; Brown et al., 1990). Indeed,
O’Neill et al. (1995) concluded that both bac-
ulovirus-derived parvoviral antigens (VP1 and
VP2) were of equivalent potency with respect to
antibody detection and that the superior sensitiv-
ity of detection obtained with respect to the native
virus may be due to the more controlled purifica-
tion conditions associated with recombinant anti-
gen purification.
Both parvovirus B19 IgM detection and PCR
detection of viral DNA are now used to detect
acute or recent parvovirus B19 infection (To¨ro¨k et
al., 1992; Cohen, 1997). In view of this, it is of
significant concern that there is no requirement
for serological test validation prior to use as a
parvovirus B19 in vitro diagnostic in most coun-
tries. In fact, no data is actually available on the
absolute performance characteristics of in vitro
diagnostic assays used widely and all previous
reports on the use of parvovirus B19 IgM detec-
tion systems have focused mainly on either com-
parative studies either between commercial kits
from different manufacturers or commercial kits
with in-house immunoassays. For instance, Sloots
and Devine (1996) reported the relative sensitivity
and specificity ranges of four commercial im-
munoassays ranging from 97–100 to 81–99%,
respectively. Notably, these authors identified
rubella IgM cross-reactivity as particularly prob-
lematic in a number of commercial immunoassay
formats. In a similar study design, Tolfvenstam et
al. (1996) evaluated the performance of a number
of commercial immunoassays using a panel of 203
clinical specimens and again noted the propensity
of some commercial parvovirus B19 IgM im-
munoassays to exhibit cross-reactivity with
rubella, Epstein–Barr virus (EBV) and cy-
tomegalovirus IgM. Furthermore, these re-
searchers noted that a false positivity rate of 5%
was evident when sera from healthy pregnant
women were analysed in some commercial im-
munoassays. In a recent study, Pickering et al.
(1998) compared commercial immunoassay per-
formance to that of an in-house immunoassay,
which uses parvovirus B19 VP1 expressed in CHO
cells, and concluded that the commercial assays
exhibited a specificity and sensitivity ranges of
91.4–93.5 and 97.4–97.5%, respectively. In our
view, this information is of limited value to the
clinical virologist in deciding which test format to
use, firstly because no information is ever pro-
vided as to absolute immunoassay performance
and secondly because in-house tests are rarely, if
ever, subject to any external regulatory or techni-
cal scrutiny. Furthermore, none of the aforemen-
tioned studies present any information relating to
immunoassay cut-off standardisation and repro-
ducibility or, more importantly, the use and ro-
bustness of the immunoassays in routine clinical
use.
Data are now described on the absolute
performance characteristics of the first parvovirus
B19 IgM enzyme immunoassay to be cleared
by the US Food and Drug Administration (FDA)
in terms of cut-off standardisation, sensitivity,
specificity, antibody class specificity, im-
munoassay reproducibility and antibody sero-
prevalence.
2. Materials and methods
2.1. Antigen production, purification and
modification
Parvovirus B19 recombinant VP2 capsids used
for parvovirus B19 IgM detection were expressed
in the baculovirus expression system using
Spodoptera frugipera cells (Brown et al., 1990,
1991). Capsid purification has been previously
described (Kerr et al., 1999) and the resultant
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capsid VP2 was biotinylated using N-hydroxysuc-
cinimid-obiotin at a 50:1 (reagent:protein) molar
ratio.
2.2. Par6o6irus B19 IgM enzyme immunoassay
The parvovirus B19 IgM enzyme immunoassay
used for this study is a mm-capture enzyme im-
munoassay for the detection of parvovirus B19
IgM in human serum and plasma (1:100 dilution).
Microwells were pre-coated with rabbit anti-hu-
man IgM and total serum IgM was bound to the
solid phase (1 h). Following a wash step, the
biotinylated VP2 capsids were added which bound
to any parvovirus B19 IgM present (30 min).
After another wash step, streptavidin-peroxidase
was added which, in turn, bound to the biotiny-
lated VP2 present (30 min). This complex was
then detected by addition of tetramethyl benzidine
(TMB) substrate. Sulphuric acid (1 N) addition
terminated the reaction after 10 min and was
followed by absorbance measurement at 450 nm.
Specimens with an index value (specimen:cut-off
absorbance ratio) less than 0.9 and greater than
1.1 were deemed nonreactive and reactive, respec-
tively. Specimens in the index range 0.9–1.1 were
deemed equivocal.
2.3. Recei6er operating characteristic (ROC)
analysis
ROC analysis was used to assess the clinical
accuracy of the parvovirus B19 IgM enzyme im-
munoassay. Here, the relative sensitivity and spe-
cificity at various decision threshold values (assay
cut-off values) were calculated following the eval-
uation of (i) a sensitivity panel from individuals
with parvovirus B19 infection diagnosed clinically
(N110) and (ii) a specificity panel of putative
cross-reactive specimens (N164), respectively.
Immunoassay sensitivity and specificity were
therefore determined as follows:
1. Sensitivity: specimens (N110) used to estab-
lish the sensitivity of the parvovirus B19 IgM
immunoassay, met the following criteria: (i)
patients were diagnosed independently by a
physician as having clinical symptoms concor-
dant with parvovirus B19 infection and (ii)
specimens were analysed using a parvovirus
B19 IgM immunofluorescent assay (IFA) to
evaluate IgM status, where possible. Hence,
the parvovirus B19 IgM immunoassay itself
was not used to classify the immune status of
the subjects in accordance with accepted
guidelines for ROC analysis (NCCLS, 1995).
It should be noted that clinical diagnosis was
taken as the primary diagnostic, thus, a speci-
men was deemed to be parvovirus B19 IgM
reactive in the case of a positive clinical diag-
nosis and an nonreactive IFA test result (two
specimens fell into this category).
2. Specificity: specimens from patients with dis-
ease states symptomatically analogous to par-
vovirus B19 infection or with putative
cross-reactive potential were tested to establish
the specificity of the parvovirus B19 IgM im-
munoassay for ROC analysis. This panel com-
prised 164 individual serum samples including
21 cytomegalovirus (CMV) IgM, 25 EBV IgM,
20 rubella IgM, five rubeola IgM, five mumps
IgM, five varicella zoster virus (VZV) IgM,
five herpes simplex virus (HSV)-1 and 2 IgM,
five parainfluenza-3 IgM, four influenza B
IgM, five mycoplasma IgM, 14 toxoplasmosis
IgM, five lyme disease IgM, 17 rheumatoid
factor, five rheumatoid arthritis, five thyroidi-
tis, five systemic lupus erythematosus and
eight with anti-nuclear antibodies (ANA).
These specimens were confirmed as mostly
strong reactives for their particular condition
using FDA cleared in vitro diagnostic devices
except thyroiditis, rheumatoid arthritis and lu-
pus sera. These conditions were diagnosed
clinically by physicians and the patients were
known to be undergoing treatment for the
specific disorders at the time of the sample
donation.
To classify further patients, all available speci-
mens were also tested by a parvovirus B19 IFA
which employs a different antigen (B19 VP1
protein) to that used in the immunoassay (B19
VP2 protein) making it an ideal standard refer-
ence test method for this purpose according to the
National Committee for Clinical Laboratory
Standards (NCCLS) guidelines. Parvovirus B19
PCR analysis was carried out essentially as de-
scribed by Dieck et al. (1999).
S. Doyle et al. : Journal of Virological Methods 90 (2000) 143–152146
2.4. Immunoglobulin class specificity
Class specificity of the immunoassay was evalu-
ated by testing specimens strongly reactive for
both parvovirus B19 IgG and IgM in the par-
vovirus B19 IgM enzyme immunoassay
as follows: parvovirus B19 IgM positive sera
(N10) were tested (i) without absorbents as a
control to demonstrate the reactive parvovirus
B19 IgM status of the sera, (ii) IgG absorbed
(goat anti-human IgG (Incstar, USA)) to show
that IgG removal does not affect significantly the
absorbance or index values relative to the
control and therefore confirm IgG is not con-
tributing to the signal, (iii) IgM absorbed (goat
anti-human IgM (Dako)) to show that IgM re-
moval eliminates the immunoassay signal thereby
demonstrating absorbent efficacy and class specifi-
city.
2.5. Immunoassay reproducibility
Intra-assay reproducibility was evaluated by
testing a panel comprising parvovirus B19 IgM
nonreactive, weakly and strongly reactive speci-
mens (N12). Each specimen was assayed a total
of 22 times. Inter-assay reproducibility data was
determined as follows: a panel of coded par-
vovirus B19 IgM nonreactive, weakly reactive and
reactive specimens (N16) was assayed across
three independent batches of the immunoassay at
three test sites over 3 days. Each specimen was
assayed three times per day (in duplicate) per
batch on 3 different days at each of three labora-
tories (N81 assays per specimen). The test
panel comprised nonreactive parvovirus B19 IgM
(serum N2, heparinised plasma N1, EDTA
plasma N1), weakly reactive parvovirus B19
IgM (serum N5, heparinised plasma N1,
EDTA plasma N1) and strongly reactive par-
vovirus B19 IgM (serum N3, heparinised
plasma N1, EDTA plasma N1) specimens.
All weakly reactive specimens were prepared
by diluting parvovirus B19 IgM reactive speci-
mens into nonreactive specimens. Linear regres-
sion analysis was used to establish
inter-laboratory (N3) and inter-batch (N3)
reproducibility.
2.6. Par6o6irus B19 IgM seropre6alence
The seroprevalence of parvovirus B19 IgM in a
US blood donor population (N399) was deter-
mined using the parvovirus B19 IgM enzyme im-
munoassay. Here, consecutive healthy donors
from two distinct locations in the USA (Houston
(N200) and Minneapolis (N199)) were in-
cluded and both age and gender criteria were
recorded. An aliquot of serum was taken from
each eligible blood donor and then tested for
parvovirus B19 IgM at the site of donation. There
was no record of a parvovirus B19 epidemic or
outbreak at the time of specimen collection.
3. Results
The relative sensitivity and specificity of the
parvovirus B19 IgM detection at various im-
munoassay cut-off values is given in Fig. 1 (ROC
plot for parvovirus B19 IgM detection). The ac-
tual immunoassay cut-off (1.0) results in a im-
munoassay sensitivity and specificity of 89.1 and
99.4%, respectively. It is clear from this data that
immunoassay sensitivity increases with decreasing
cut-off value with a concomitant decrease in spe-
cificity. The clinical accuracy of the immunoassay
is evident given the position of the selected cut-off
in the upper left-hand quadrant of the plot.
Of the 110 parvovirus B19 clinical specimens
tested to establish immunoassay sensitivity, 99
Fig. 1. ROC plot of the parvovirus B19 IgM enzyme im-
munoassay. The selected cut-off value is indicated with an
arrow.
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Table 1
Parvovirus B19 IgM enzyme immunoassay specificitya
No. ofSpecimen Type Number reactive
Specimens
21Cytomegalovirus 0:21
1:25b25EBV
20Rubella 0:20
5Rubeola 0:5
0:55Mumps
0:5Varicella zoster virus 5
0:55Herpes simplex virus-1
5Herpes simplex virus-2 0:5
0:5Parainfluenza 3 5
0:44Influenza B
5Mycoplasma 0:5c
14Toxoplasma gondii 0:14
0:55Lyme disease
17Rheumatoid factor 0:17
5Rheumatoid arthritis 0:5
0:55Thyroiditis
5 0:5Systemic lupus
erythematosus
Anti-nuclear antibody 2:8*8
a Evaluation of specimens (N164) from patients with spe-
cific viral disease states or parvovirus B19 infection-like symp-
toms.
b One EBV IgM and two ANA specimens which were
reactive in the parvovirus B19 IgM enzyme immunoassay were
also tested by parvovirus B19 immunoblot and immu-
nofluorescent assays and were found to be reactive in both
formats. Because the likelihood of genuine parvovirus B19
IgM reactivity cannot be eliminated they were excluded from
the ROC analysis.
c One mycoplasma specimen tested equivocal.
cross-reactivity was observed with a wide range of
symptomatically similar viral infections including
cytomegalovirus, rubella, mumps, VZV, rubeola,
HSV-1 and 2. Of these 164 specimens used to
evaluate immunoassay specificity for ROC analy-
sis, only three exhibited apparent cross-reactivity
whereby 1:21 EBV IgM specimens and 2:8 ANA
specimens were reactive by the parvovirus B19
IgM immunoassay. Notably, the EBV IgM speci-
men and both ANA specimens were also reactive
following parvovirus B19 IgM analysis by IFA
and Western blot detection systems (data not
shown). Insufficient EBV specimen volume was
available for PCR analysis, however 1:2 ANA
specimens was PCR positive. No reactivity was
observed with all other disease states which may
produce B19 infection-like symptoms and speci-
mens which were from rheumatoid arthritis or
lupus erythematosus patients, or contained
rheumatoid factor, were nonreactive in the im-
munoassay (Table 1). Specimens obtained from
toxoplasmosis (N14) and lyme disease infected
individuals (N5) were also completely nonreac-
tive in the parvovirus B19 IgM immunoassay. No
evidence of significant cross-reactivity was de-
tectable in mycoplasma, parainfluenza 3 and
parainfluenza B IgM specimens tested by the par-
vovirus B19 IgM immunoassay, however 1:5 my-
coplasma IgM specimens did give equivocal
results on two occasions.
The parvovirus B19 IgM immunoassay is spe-
cific for parvovirus B19 IgM detection. Neither
the presence or subsequent removal of parvovirus
B19 IgG affects parvovirus B19 IgM analysis.
Removal of total IgM from the ten parvovirus
B19 IgM reactive specimens produces the ex-
pected negative result thereby confirming the im-
munoglobulin class specificity of the device.
Intra-assay reproducibility of the parvovirus
B19 IgM enzyme immunoassay is extremely high
and, expressed as percentage coefficient of varia-
tion (%CV), ranges from 8.2% for weakly reactive
specimens to 5.1% for strongly reactive specimens,
respectively (Table 2). Inter-assay reproducibility
was extensively investigated whereby a blinded
panel of specimens (N16) was tested using three
batches of parvovirus B19 IgM immunoassay at
each of three test sites (Table 3). All four nonreac-
(90%) were found to contain detectable par-
vovirus B19 IgM by immunoassay. The majority
of the remaining specimens (7:11), gave index
values greater than 0.6 which indicates the pres-
ence of very low levels parvovirus B19 IgM below
the immunoassay cut-off value. A parvovirus B19
IgM IFA, which uses parvovirus B19 VP1 anti-
gen, was used to determine parvovirus B19 IgM
presence in 84 of the 110 clinical specimens. Three
specimens which were reactive in the enzyme im-
munoassay were nonreactive by IFA and six non-
reactive immunoassay specimens were weakly
reactive by IFA.
Data presented in Table 1 shows immunoassay
specificity when challenged with specimens from
specific viral infection and disease states. No
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tive and five strongly reactive specimens, which
were each tested a total of 81 times, were iden-
tified correctly on all occasions. Thus, 403 (81
5) and 324 (814) individual specimen analyses
gave the expected result. The weakly reactive
specimens (N7) which all produced index or
optical density (OD) values proximal to the im-
munoassay cut-off were correctly identified in
542:567 (95.5%) occasions. Thus, in a combined
specimen analysis of 1294 tests, 98.1% of results
were as expected.
Total inter-assay reproducibility (excluding
data from nonreactive test specimens), ranges
from 11.8 to 17.5%CV or 18.0 to 29.5%CV when
expressed in terms of either index or OD values,
respectively (Table 3). Linear regression analysis
of inter-site data confirms the high reproducibility
and robustness associated with the immunoassay
and correlation coefficients of 0.99 were observed
for both index and OD values, respectively, for
both inter-site (site 1 vs. 2, site 2 vs. 3 and 1 vs. 3)
and inter-batch comparative scenarios.
The overall rate of parvovirus B19 IgM
seropositivity is 1% (4:399). Results from each of
the two population groups dispersed geographi-
cally show that the seroprevalence of parvovirus
B19 IgM is low with rates of 0.5% (1:200) and
Table 3
Inter-assay reproducibility of the parvovirus B19 IgM enzyme
immunoassaya
Specimen Mean OD NS.D. %CV (%CV-index)
0.039 81UR-1S 23.20 (23.50)0.009
0.038 0.012UR-2S 32.68 (29.64) 81
0.034UR-3E 8130.67 (30.39)0.011
UR-4H 8132.84 (32.79)0.0110.034
WR-1S 810.462 0.113 24.39 (16.77)
0.429 0.104WR-2S 24.37 (15.84) 81
WR-3E 0.407 0.108 26.40 (16.62) 81
8124.42 (17.34)0.083WR-4S 0.341
0.347 0.095WR-5S 27.23 (17.46) 81
WR-6S 0.305 0.087 28.48 (17.10) 81
WR-7H 0.303 0.090 29.52 (17.24) 81
SR-1S 8120.06 (13.58)0.2261.128
19.37 (15.14)0.233 811.201SR-2E
SR-3H 1.204 0.229 19.04 (11.76) 79
8118.02 (13.29)0.199SR-4S 1.103
SR-5S 811.023 0.198 19.36 (12.36)
a Sixteen specimens ranging in Parvovirus B19 IgM levels
from nonreactive to strongly reactive were tested. Data was
accumulated over three test sites and three batches of par-
vovirus B19 IgM enzyme immunoassay over a 3-day period.
OD, optical density (450:620 nm); index: ratio specimen:cut-
off value OD; UR, nonreactive; WR, weakly reactive; SR,
strong reactive; S, serum; E, EDTA plasma; H, heparinised
plasma.
1.5% (3:199) from Houston and Minneapolis, re-
spectively. Of the 399 specimens tested, six speci-
mens were either weakly reactive (N3) or
equivocal (N3) after initial testing. Upon retest-
ing of the three equivocal specimens, one re-
mained equivocal, one tested negative and one
was weakly reactive. Follow-up samples were not
available to confirm the equivocal result. Conse-
quently, 99% (394:399) specimens were nonreac-
tive for parvovirus B19 IgM, four were reactive
and one was equivocal. The parvovirus B19 IgM
serological data from the 399 US blood donors
expressed in terms of index values (ratio of speci-
men:cut-off OD value) demonstrates that the ma-
jority of specimens from the healthy blood donors
have index values which are well below the assay
cut-off value. Only a small minority of samples
(N5) have index values approaching the cut-off
value.
The seroprevalence of parvovirus B19 IgM in
women of child-bearing age was also evaluated in
Table 2
Intra-assay reproducibility expressed in terms of OD on 22
replicates of each of 12 different serum specimens ranging in
parvovirus B19 IgM levels from nonreactive to strongly
reactivea
NS.D. %CVSpecimen Mean OD
0.02 9.43 22UR-K 0.002
0.03 3.91 22UR-L 0.002
0.59WR-D 0.02 4.12 22
4.73 22WR-E 0.46 0.02
4.380.02 220.45WR-F
0.45 0.037WR-G 228.20
WR-H 227.320.020.22
5.16 22WR-I 0.010.29
5.480.010.20WR-J 22
225.100.074SR-A 1.46
220.024SR-B 2.441.002
0.99 0.02SR-C 221.87
a OD, optical density (450:620 nm); index: ratio specimen:
cut-off value OD; SR, strong reactive; WR, weak reactive;
UR, nonreactive.
S. Doyle et al. : Journal of Virological Methods 90 (2000) 143–152 149
females from both Minneapolis and Houston
(N181). The overall rate of positivity in this
group was 1.65% (3:181) which was not signifi-
cantly different from the reminder of the test
population (P0.33, Fischers Exact Test).
4. Discussion
The data presented represents the most exten-
sive report to date of the performance of a par-
vovirus B19 IgM enzyme immunoassay available
commercially. The report clearly indicates the
very high specificity and sensitivity of the im-
munoassay and confirms that the selected cut-off
value facilitates the accurate detection of par-
vovirus B19 IgM. ROC analysis is a powerful tool
used to assess the clinical accuracy of laboratory
tests (Zweig and Campbell, 1993; NCCLS, 1995).
In this study, such an analysis was applied, for the
first time, to the determination of the clinical
accuracy of a parvovirus B19 IgM immunoassay.
When plotted on a ROC curve, the resultant data
clearly demonstrates that the parvovirus B19 IgM
immunoassay provides a means of classifying par-
vovirus B19 IgM status (Fig. 1). The test comes
very close to being optimal (100% sensitivity and
specificity is represented by inflection in the upper
left-hand quadrant) insofar as the closer the plot
comes to this point the greater the serological
distinction between patients with parvovirus B19
infection and patients exhibiting similar
symptomologies.
Using the current immunoassay cut-off, the
observed specificity exceeds 99% and the sensitiv-
ity is almost 90% which provides maximum assay
specificity thus ensuring accurate diagnosis of par-
vovirus B19 infection. Greater assay sensitivity
could be obtained by reducing the cut-off value
with a slight compromise on specificity. This may
be of significance in the analysis of certain patient
populations (e.g. immunocompromised individu-
als) for evidence of recent parvovirus B19 infec-
tion. The majority of specimens (N9:11) which
tested parvovirus B19 IgM negative were obtained
4–15 months post-parvovirus B19 IgM serocon-
version, thus the amount of antibody present may
have been insufficient to be detected as a reactive
specimen at the selected immunoassay cut-off.
Five of these nine specimens were very weakly
reactive by IFA, possibly reflecting a slightly ele-
vated sensitivity of this assay format. It is our
view that specificity of detection with regard to
exposure to parvovirus B19 is more important
than sensitivity of detection given the somewhat
non-specific and sometimes confusing symptoms
associated with parvovirus B19 infection (Jensen
and Vestergaard, 1997). Indeed many other viral
infections, particularly rubella, induce symptoms
similar to parvovirus B19 (Thomas et al., 1999;
Turner, 1999). However, for optimal assessment
of the likelihood of infection and determination of
the risk of fetal hydrops in pregnancy, serological
analysis should also determine the parvovirus B19
IgG status of the patient and follow up specimens
should be drawn from the patient, where possible
(Searle et al., 1997).
The parvovirus B19 IgM immunoassay demon-
strated no cross-reactivity whatsoever with sera
from viral disease states such as rubella, CMV,
VZV, mumps or rubeola, all of which could theo-
retically be confused with parvovirus B19 infec-
tion. This is highly significant since previous
reports of parvovirus B19 immunoassays have
nearly all reported significant cross-reactivity with
rubella and CMV IgM (Sloots and Devine, 1996;
Tolfvenstam et al., 1996). Of the 164 potentially
cross-reactive specimens tested in this study, only
6 specimens were reactive when equivocal results
are included as false positive. These EBV (N2)
and mycoplasma (N1) specimens which were
reactive or equivocal in the immunoassay were
also tested using a parvovirus B19 IgM IFA and
Western blot assay (Kerr et al., 1999). The EBV
specimens were found to be strongly reactive in
both assays. These assays confirmed antibody re-
activity with parvovirus B19 VP1 structural
protein which is not present in the VP2-based
parvovirus B19 IgM immunoassay. Thus, it is
possible that EBV reactivation of lymphocytes
capable of producing parvovirus B19 IgM is re-
sponsible for this apparent cross-reaction (Alpers
et al., 1994). The mycoplasma sample which gave
repeatedly equivocal results using the parvovirus
B19 IgM immunoassay was nonreactive in both
parvovirus B19 IgM IFA and Western blot, possi-
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bly because the level of antibody may have been
too low to be detected by these methods or be-
cause of genuine cross-reactivity. The ANA posi-
tive sera which were reactive using the parvovirus
B19 IgM immunoassay were also reactive when
tested in the parvovirus B19 assays described
above and one of the two ANA specimens was
also PCR positive. This finding may be of clinical
significance since parvovirus B19 has been impli-
cated in the development of certain autoimmune
diseases with associated the presence of ANA
(Fawaz-Estrup, 1996). It is important to note that
in the occasional cases of apparent false positivity,
the samples exhibiting the highest titre for the
specific infection (EBV and mycoplasma) or dis-
ease state (ANA) were not those which exhibited
false positivity in the parvovirus B19 IgM im-
munoassay. This is further evidence that the mass
or avidity of potential cross-reactants may not be
responsible for the observed results and that gen-
uine reactivity in the parvovirus B19 im-
munoassay may be present.
Previous studies on the performance evaluation
of parvovirus B19 IgM immunoassays have given
only very limited information with regard to im-
munoassay reproducibility (Sloots and Devine,
1996). The data presented above represents the
most comprehensive report of the true intra-assay
and inter-assay reproducibility, comprising inter-
batch and inter-site studies, of a parvovirus B19
IgM immunoassay to date. Intra-assay reproduci-
bility data, whereby coefficients of variation range
from 5.1 to 8.2%, confirm not only the accurate
coating of capture antibody [anti-human IgM] but
also the extent to which individual immunoassay
steps have been optimised (Table 2). Inter-assay
reproducibility data has been generated from the
analysis of 16 blinded specimens of various par-
vovirus B19 IgM reactivities at three test sites,
incorporating three tests per day by different ana-
lysts, over a 3-day period using three batches of
immunoassay (Table 3). Consequently, each speci-
men has been tested a total of 81 times. The
resultant %CV (minimum 11.8% for strongly reac-
tive to maximum 17.5% for weakly reactive speci-
mens) are highly acceptable especially when one
considers that all strongly reactive and nonreac-
tive specimens were diagnosed correctly. Weakly
reactive specimens were detected correctly on 542:
567 (95.5%) of occasions and were either equivo-
cal (N19:567; 3.35%) or nonreactive
(N6:567; 1.1%) in the remainder of cases. It is
likely that a combination of close proximity to the
immunoassay cut-off and minor non-homogeneity
in specimen matrices during test panel prepara-
tion may have been responsible for this observa-
tion. A finding borne out by the fact that two
specimens in particular (WR-6S and WR-7H),
each with a mean index of 1.36, were responsible
for the majority (N21:25) of weakly reactive to
equivocal:nonreactive fluctuations. The observed
inter-site and inter-batch correlation data (r2
0.99) is particularly important as it serves to
confirm maximum inter-batch consistency and the
diagnostic accuracy of the parvovirus B19 IgM
immunoassay in different laboratories. This is of
particular significance given the general lack of
regulatory requirements for parvovirus B19 anti-
body detection, particularly throughout the Eu-
ropean Union.
The seroprevalence study demonstrates that the
total rate of parvovirus B19 IgM positivity is
0.5% (1:200) and 1.5% (3:199), respectively, in
two US populations distinct geographically with
an overall rate of 1.0% parvovirus B19 IgM posi-
tivity observed when both populations are com-
bined (N399). Notably, the reactive samples
detected were either in or slightly above the equiv-
ocal range of the parvovirus B19 IgM im-
munoassay whereas nonreactive specimens are
well displaced from the immunoassay cut-off. The
majority of samples (N348) have index values
less than 0.3 (mean index0.15) which is well
below the cut-off index of 1.00.
The seroprevalence rate of 1.65% (3:181) ob-
served in the sub-population of women of child-
bearing age was not significantly different to that
in the remainder of the study population. In a
similar study carried out in Europe using the
parvovirus B19 IgM immunoassay, a population
of Irish blood donors gave a parvovirus B19 IgM
seroprevalence rate of 1:417 (0.24%) or 0.72% if
two equivocal test results were included as reac-
tives (data not shown). In addition, Searle et al.,
(1997) have observed a parvovirus B19 IgM sero-
prevalence of 2.34% in cohort of 939 German
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women following exposure to, or suspicion of
infection with, parvovirus B19 during pregnancy.
Further studies using a larger population cohort
may help clarify the significance of the observed
difference in parvovirus B19 IgM seropositivity
between the two groups in the present report.
In summary, data are presented which provide
for the first time information both on the perfor-
mance of a parvovirus B19 IgM enzyme im-
munoassay in terms of absolute cutoff
standardisation-using ROC analysis, and a com-
prehensive multi-site evaluation of immunoassay
reproducibility. This information will be of use to
the clinical virologist in understanding the reli-
ability of current parvovirus B19 serological as-
says in the absence of significant international
standards for the performance criteria required
for accurate detection of recent infection with
parvovirus B19.
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